SYK-selective kinase inhibitor
oral, completed Ph. I in HV
from optimization of prior candidate
ACS Med. Chem. Lett. Feb. 12, 2020
Gilead Sciences, Seattle, WA
GS-9876 (lanraplenib)
1 min read
GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)
Search By Structure
- LNP023
- LMB763 (nidufexor)
- ABBV-744
- AG-881
- FT-2102 (olutasidenib)
- GS-9876 (lanraplenib)
- “compound 25”
- “compound 25”-2
- WF-47-JS03
- BMS-986260
- GNF2133
Molecules of the Month
2023
2022
2021
2020